Business
Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream
Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nCipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream\nCanada NewsWire\nMISSISSAUGA, ON, May 2, 2016\n\n\n\nProduct candidate may have the potential to transform tattoo removal process\n\n\n\nMISSISSAUGA, ON, May 2, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (\"Cipher\" or \"the Company\") today announced it has licensed the worldwide rights to develop and commercialize an investigational tattoo removal cream being developed at Dalhousie University in Halifax, Nova Scotia by Alec Falkenham, a PhD student in the Department of Pathology at Dalhousie University. The product candidate, which is applied topically, has shown encouraging results in pre-clinical testing for the removal or reduction of the appearance of tattoos. \n\n\"This technology has the potential to transform the process of tattoo removal and may give people the option of a topical cream instead of laser treatments, which are painful, costly and time-consuming,\" said Shawn O'Brien, President and CEO of Cipher. \"As we continue to build our pipeline, we will complement our predominantly late-stage assets with investments in select early-stage product candidates that we believe have high potential and can be commercialized efficiently.\"\n\nThe agreement was fostered through Dalhousie's Industry Liaison and Innovation office. \n\n\"We are very pleased to have Cipher Pharmaceuticals partner with Dalhousie University on this innovation,\" says Dr. Martha Crago, Vice-President Research at Dalhousie University. \"It is important for Dalhousie to partner with a company that has the experience and expertise to bring an innovation like this to market. We are also extremely proud of the hard work and research of Dalhousie student, Alec Falkenham. This is an exciting moment for him and for the university.\"\n\n\"I am very pleased and excited t...